Strategic Business Transformation
Fredun Pharmaceuticals is transforming from a conventional manufacturing-led pharmaceutical company into a brand-led healthcare platform. The H1 FY27 strategy focuses on multiple high-growth engines including strategic investments in pet-care ecosystem, premium wellness brands, manufacturing capacity expansion, and transition towards a 100% branded portfolio by 2029.
Pet Care Ecosystem Developments
Goodman Vetcare Investment
- Acquired 26% stake in Goodman Vetcare Private Limited at valuation of ₹300 crore
- Goodman Vetcare operates three stores across Mumbai and Navi Mumbai
- Plans to add at least eight new stores across three cities
- Targeted revenue opportunity of approximately ₹100 crore by FY31
Furlicks Acquisition
- Acquired Furlicks oral-strip pet-wellness brand from USV and its subsidiary Wellbeing Nutrition
- Plans to introduce 16 new products over next 6-9 months
- Portfolio expansion from 6 SKUs to 22 SKUs
WAGR Platform
- Technology-enabled pet-parenting platform
- Building India's largest modern pet parenting ecosystem
- Bringing together pet-care brands, pharmacies, services, expert guidance and solutions
Strategic Shift and Financial Targets
- Transitioning from OEM-led business to 100% branded portfolio by 2029
- Targeting doubling of revenue and profitability over next 3-4 years
- Creating potential operating and valuation re-rating opportunity
Capacity Expansion
- ~40,000 sq. ft. utility block at Palghar expected operational in October 2026
- Additional 50,000 sq. ft. planned
- Working towards building India's largest single-location pharma plant
- Capacity build-out to support expanding branded portfolio and future growth ambitions
Business Segment Expansion
Domestic Generics
- Expanding domestic generics business through Fredun Gx
- Targeting 500+ SKUs across Tier 2-4 cities
Global Expansion
- Established 53-country export base
- Platform for further expansion across Latin America, Africa and Southeast Asia
Capital Structure Changes
Bonus Share Allotment
- Allotted 1.10 crore bonus equity shares on July 17, 2026
- Equity share base increased from 55.13 lakh to 1.65 crore shares
Warrant Conversion
- 3,61,599 equity shares allotted in September 2026
- Following conversion of warrants held by non-promoter investors
Key Strategic Positioning
Fredun is positioning itself as an integrated, multi-category branded healthcare platform with transformation path: OEM Manufacturing → Owned Brands → Premium Wellness → Pet Healthcare → Digital Pet Ecosystem → Global Expansion
Disclaimer
Document contains forward-looking statements subject to risks and uncertainties including government actions, economic developments, technological risks, and other factors that could cause actual results to differ materially. Company undertakes no obligation to update these statements.